Anifrolumab (Saphnelo) listed in SK

May 1, 2024 – Lupus Canada is pleased to share that Lupus Awareness Month is kicking off with a Saphnelo listing in Saskatchewan effective May 1st, 2024.  With this listing, Saphnelo is now covered by 86% of Canadian public drug reimbursement plans.

For more information, you can visit the Saskatchewan Drug Plan website and enter ‘anifrolumab’ into the search bar or view the May Saskatchewan Formulary Bulletin.

Lupus Blog Articles:

Advocacy Toolkit for Individuals: Empowering the Lupus Community

Read

Supporting Lupus Canada During Canada Post Strike

Read

New Resource: CANVAS Network for Vaccine Safety

Read